Oppenheimer Holdings, Inc. Reaffirms “Hold” Rating for Insys Therapeutics, Inc. (INSY)
Insys Therapeutics, Inc. (NASDAQ:INSY)‘s stock had its “hold” rating restated by stock analysts at Oppenheimer Holdings, Inc. in a report released on Sunday.
A number of other research analysts also recently commented on INSY. Zacks Investment Research downgraded Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 9th. TheStreet downgraded Insys Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, August 21st. BidaskClub downgraded Insys Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, August 11th. Royal Bank Of Canada reduced their price target on Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, August 4th. Finally, Piper Jaffray Companies set a $10.00 price target on Insys Therapeutics and gave the company a “hold” rating in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $9.38.
Shares of Insys Therapeutics (INSY) traded down $0.05 on Friday, reaching $5.16. The company had a trading volume of 485,500 shares, compared to its average volume of 777,138. Insys Therapeutics has a 1 year low of $4.10 and a 1 year high of $15.02.
TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/13/oppenheimer-holdings-inc-reaffirms-hold-rating-for-insys-therapeutics-inc-insy.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in INSY. Dynamic Technology Lab Private Ltd acquired a new stake in Insys Therapeutics during the third quarter valued at approximately $119,000. SG Americas Securities LLC acquired a new stake in Insys Therapeutics during the second quarter valued at approximately $138,000. Voya Investment Management LLC acquired a new stake in Insys Therapeutics during the second quarter valued at approximately $149,000. American International Group Inc. raised its stake in Insys Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 953 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in Insys Therapeutics by 213.2% during the second quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock valued at $166,000 after buying an additional 8,940 shares in the last quarter. Hedge funds and other institutional investors own 25.23% of the company’s stock.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Stock Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related stocks with our FREE daily email newsletter.